144 related articles for article (PubMed ID: 7055802)
21. Estrogen receptor and proteolytic activity in human breast tumor nuclei.
Garola RE; McGuire WL
Cancer Res; 1977 Sep; 37(9):3329-32. PubMed ID: 301774
[TBL] [Abstract][Full Text] [Related]
22. Estrogen receptors in human breast cancer. I. Specificity of the histochemical localization of estrogen receptors using an estrogen-albumin FITC complex.
van Marle J; Lindeman J; Ariens AT; Labruyère W; van Weeren-Kramer J
Virchows Arch B Cell Pathol Incl Mol Pathol; 1982; 40(1):17-25. PubMed ID: 6126951
[TBL] [Abstract][Full Text] [Related]
23. [Important "reference conditions" in the interpretation of hormone receptor findings in human breast carcinomas. Studies of the nude mouse model].
Michel RT; Bastert G
Med Welt; 1983 Mar; 34(12):373-7. PubMed ID: 6855536
[No Abstract] [Full Text] [Related]
24. Estrogen receptors in the spectrum of breast cancer.
Leclercq G; Heuson JC
Curr Probl Cancer; 1976 Dec; 1(6):1-34. PubMed ID: 798657
[No Abstract] [Full Text] [Related]
25. Estrogen binding sites in the nucleus of normal and malignant human tissue: optimization of an exchange assay for the measurement of specific binding.
Syne JS; Markaverich BM; Clark JH; Panko WB
Cancer Res; 1982 Nov; 42(11):4443-8. PubMed ID: 7127286
[TBL] [Abstract][Full Text] [Related]
26. (3H)Tamoxifen binding studies in dimethylbenzanthracene-induced mammary carcinomata [proceedings].
Nicholson RI; Daniel CP; Davies P; Griffiths K
J Endocrinol; 1977 Dec; 75(3):26P. PubMed ID: 591830
[No Abstract] [Full Text] [Related]
27. Specific estrogen receptor binding and biological effects of 16 alpha-iodoestradiol on human breast cancer cells.
Lippman ME; Do HM; Hochberg RB
Cancer Res; 1981 Aug; 41(8):3150-4. PubMed ID: 7248972
[TBL] [Abstract][Full Text] [Related]
28. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
29. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
30. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
31. The scientific basis of a fluorescent histochemical estrogen receptor (ER) assay for breast cancer.
Lee SH
Pathologica; 1985; 77(1049):229-30. PubMed ID: 3831878
[No Abstract] [Full Text] [Related]
32. Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer.
Moiseeva EV; Rapoport EM; Bovin NV; Miroshnikov AI; Chaadaeva AV; Krasilshschikova MS; Bojenko VK; Bijleveld C; van Dijk JE; Den Otter W
Breast Cancer Res Treat; 2005 Jun; 91(3):227-41. PubMed ID: 15952056
[TBL] [Abstract][Full Text] [Related]
33. Relationship of cytoplasmic and nuclear estrogen receptors and progesterone receptors in human breast cancer.
Romić-Stojković R; Gamulin S
Cancer Res; 1980 Dec; 40(12):4821-5. PubMed ID: 7438115
[TBL] [Abstract][Full Text] [Related]
34. Polymorphism of estrogen receptors in human breast cancer.
Wittliff JL; Feldhoff PW; Fuchs A; Wiehle RD
Prog Clin Biol Res; 1981; 74():375-96. PubMed ID: 6275406
[No Abstract] [Full Text] [Related]
35. Estradiol and progersterone receptors in F1 (C3H X RIII) mice mammary tumors: effect of castration.
Edery M; Drosdowsky MA
Biomedicine; 1980 May; 33(3):80-2. PubMed ID: 7448327
[TBL] [Abstract][Full Text] [Related]
36. Expression of CD44 isoforms in human breast carcinoma xenografts is not influenced by the treatment of mice with cytostatics or (anti-)hormones.
Dehmel A; Becker M; Lemm M; Fichtner I
Anticancer Res; 1999; 19(3A):1977-87. PubMed ID: 10470143
[TBL] [Abstract][Full Text] [Related]
37. Nuclear oestrogen receptor and breast cancer.
Lancet; 1977 Oct; 2(8040):714-6. PubMed ID: 71522
[No Abstract] [Full Text] [Related]
38. Neuroendocrine abnormalities and the pathogenesis of estrogen-receptor-positive breast cancer.
Lehrer S; Brown RR; Lee C; Kalnicki S; Lipsztein R; Bloomer WD
Mt Sinai J Med; 1988 Sep; 55(4):272-5. PubMed ID: 3070373
[No Abstract] [Full Text] [Related]
39. Fine needle biopsy in estrogen receptor determination in breast cancer.
Lindgren A; Sällström J; Adami HO
Eur J Cancer (1965); 1980; Suppl 1():67-9. PubMed ID: 7318872
[No Abstract] [Full Text] [Related]
40. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis.
Kampa M; Nifli AP; Charalampopoulos I; Alexaki VI; Theodoropoulos PA; Stathopoulos EN; Gravanis A; Castanas E
Exp Cell Res; 2005 Jul; 307(1):41-51. PubMed ID: 15922725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
